Redaktion

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Psoriasis is a chronic inflammatory skin disease affecting millions of people worldwide. Although growing evidence links chronic inflammation with increased cancer risk, the association between psoriasis and cutaneous squamous cell carcinoma (cSCC) is still elusive. Using cell transplantation and chemical-induced models of cSCC combined with inducible genetically engineered mouse models of psoriasis, we investigated how chronic skin and systemic inflammation affects squamous skin tumor initiation and progression. Here we show that in the context of severe psoriasis-like disease, neutrophil-dependent inflammation prevents squamous skin tumor development. Cellular and molecular analyses of psoriasis-like skin at the tumor initiation stage revealed a marked infiltration of CD54-expressing neutrophils, associated with the release of cytotoxic granules and neutrophil extracellular traps (NETs), as well as enhanced senescence and the expression of senescence-associated secretory phenotype in keratinocytes. Furthermore, single-cell RNA sequencing demonstrated that inflammatory N1-like neutrophils mediate reprogramming of the cell-cell communication networks, while keratinocytes displayed diminished responsiveness to mitogenic signals, including epidermal growth factor and Wnt/β-catenin. Importantly, neutrophil depletion ameliorated psoriasis-like inflammation, abolished the senescence-like phenotype in keratinocytes and restored tumor growth. We propose that the release of neutrophil granules and NETs in psoriasis-like skin eliminate tumor cells and/or mediate oxidative and inflammatory stress-induced senescence in keratinocytes, thereby preventing tumor growth. Taken together, we have defined an innate control of skin tumorigenesis in psoriasis-like disease, which will be relevant for developing cancer prevention strategies.Weiterlesen

To investigate bimekizumab efficacy in scalp, nail and palmoplantar psoriasis.In this analysis, data are included from the BE SURE, BE VIVID, BE READY, and BE RADIANT phase 3/3b trials (48-56 weeks) and BE BRIGHT open-label extension (144 weeks). Adults with moderate to severe plaque psoriasis and scalp/palmoplantar Investigator's Global Assessment (IGA) score ≥3 or modified Nail Psoriasis Severity Index (mNAPSI) >10 at baseline were randomized to bimekizumab or comparators (adalimumab, ustekinumab, secukinumab, placebo). Higher rates of complete clearance of scalp and palmoplantar psoriasis were generally observed at Week 4 with bimekizumab than comparators.At Week 24, rates of complete resolution of scalp/nail/palmoplantar psoriasis were 77.7%/39.8%/78.7% with bimekizumab and 58.1%/24.5%/73.3% with adalimumab; at Week 52, 71.9%/54.0%/85.2% with bimekizumab and 51.8%/30.6%/75.0% with ustekinumab; and at Week 48, 80.6%/69.5%/82.4% with bimekizumab and 71.6%/52.5%/76.8% with secukinumab. Complete scalp/nail/palmoplantar clearance rates were sustained through 4 years' bimekizumab treatment (79.5%/61.6%/88.7%). Bimekizumab consistently showed higher rates of complete clearance of psoriasis in high-impact areas along with greater patient-reported health-related quality of life benefits than comparators. Responses were sustained over 4 years, which may lead to improvements in patients' quality of life.Trial registrationBE SURE (NCT03412747), BE VIVID (NCT03370133), BE RADIANT (NCT03536884), BE READY (NCT03410992), BE BRIGHT (NCT03598790).Weiterlesen

ObjectivePsoriasis is a chronic inflammatory autoimmune disease that affects physical and mental health. Mental stress has been shown to exacerbate human psoriasis by unknown mechanism.MethodsPeripheral blood mononuclear cells (PBMCs) were collected from patients with psoriasis and mental stress-treated psoriatic mice. The expression levels of TLR9/MyD88/NF-κB pathway-related molecules were analyzed by qRT-PCR and western blotting. Histological examination of skin lesions was examined using hematoxylin-eosin staining. The ratios of Treg/CD4+T cells and Th17/Treg cells were determined by flow cytometry. The associations among mental stress, the TLR9/MyD88/NF-κB pathway, and psoriasis were explored using pharmacological inhibitors and lentiviral transfection.ResultsOur findings demonstrated a significant upregulation of TLR9/MyD88/NF-κB pathway-associated molecules in the PBMCs of psoriasis patients, accompanied by elevated expression of inflammatory factors. These observations were validated using a mouse model of psoriasis. Notably, mental stress was shown to activate the TLR9/MyD88/NF-κB pathway and enhance inflammatory factor production, while simultaneously increasing the Th17/Treg ratio and decreasing the Treg/CD4+T ratio. Therapeutic interventions including antipsychotic sertraline, pathway-specific inhibitors, and lentiviral transfection significantly ameliorated inflammatory markers and improved psoriasis severity grading.ConclusionThe results of this study demonstrates that mental stress induces inflammation and immune dysregulation, exacerbating psoriasis progression. These findings provide valuable insights into the pathophysiological mechanisms underlying psoriasis progression, particularly the mental stress-mediated immunoregulatory axis.Weiterlesen

IntroductionGeneralized pustular psoriasis (GPP) is rare, chronic, and associated with life-threatening complications. We investigated the burden of GPP in France.MethodsUsing data from 2010 to 2021 in the Système National des Données de Santé database, healthcare resource utilization (HCRU), costs, comorbidities, mortality, and treatments were compared among GPP (N = 4351), plaque psoriasis (N = 12,945), and general population (N = 12,981) cohorts, matched for sex, age, Charlson Comorbidity Index (CCI) score, and region. GPP prevalence and incidence were also investigated.ResultsAnnually, there were 0.5-0.8 new GPP cases per 100,000 people. Across the cohorts, 54.5-54.7% of people were male, with mean age 58.7-59.5 years and mean CCI score 1.98-2.06. The GPP cohort incurred significantly greater HCRU and costs versus the plaque psoriasis and general population cohorts, including greater proportions of patients receiving emergency care (78% vs 63% and 55%) and intensive care (28% vs 17% and 14%), longer hospitalizations (mean 38.5 vs 26.2 and 22.4 days per patient), and higher medication costs (€4360 vs €1991 and €1543 per patient-year), respectively. Despite similar CCI scores, GPP was associated with more cardiometabolic and psychological comorbidities versus the plaque psoriasis and general population cohorts, e.g., hypertension (37% vs 21% and 20%), obesity (21% vs 9% and 6%), depression (13% vs 4% and 4%), alcohol abuse (16% vs 3% and 3%), and sleep disorders (8% vs 4% and 3%), respectively. Treatments in the GPP cohort were those used for plaque psoriasis, including topical steroids (77%), systemic steroids (50%), and biologics (23%). Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population).ConclusionHCRU, costs, and comorbidities with GPP were often double those for comparator cohorts, and mortality was higher. These findings highlight the need to use GPP-targeted treatments that improve patient outcomes and may reduce the burden on healthcare systems.Weiterlesen

[This corrects the article DOI: 10.1371/journal.pone.0321140.].Weiterlesen

Abstract Psoriasis, a chronic and recurring disease, is closely associated with lipid metabolism. This study aims to identify differentially expressed genes (DEGs) and their functional pathways associated with psoriasis to uncover new therapeutic targets. We leveraged Gene Expression Omnibus (GEO) datasets for DEGs analysis in psoriasis. Gene Set Enrichment Analysis (GSEA), Gene Set Variation Analysis (GSVA), Weighted Gene Co-expression Network Analysis (WGCNA), and single-sample GSEA (ssGSEA) were used to investigate the roles of lipid metabolism genes in psoriasis progression and immune alterations. An RBP-mRNA network revealed post-transcriptional regulatory mechanisms. Our findings revealed 3,839 DEGs, including 1,775 upregulated and 2,064 downregulated genes in psoriatic samples compared to controls. Enrichment analysis showed that immune-related pathways such as cytoplasmic DNA sensing pathways and NOD-like receptor signaling pathways were significantly enriched. WGCNA identified modules highly correlated with lipid metabolism and screened out key genes such as AACS, HSD11B1 and GATA6. ROC curve analysis showed that these genes had a high discriminatory ability (AUC > 0.85) within the analyzed dataset, suggesting their potential as novel biomarkers. Immune infiltration analysis revealed significant differences in 27 types of immune cells between patients with psoriasis and the control group. This study provides new clues for the molecular mechanism of psoriasis and potential therapeutic targets. Weiterlesen

Background and objectivesSystemic inflammation indices derived from complete blood counts (CBC) are accessible markers of inflammatory burden, but their relationship with circulating cytokines in psoriasis remains unclear. We investigated associations between CBC-derived indices and serum cytokines in psoriasis.Materials and methodsIn this cross-sectional study, we included 28 patients with psoriasis and 23 healthy controls. Serum IL-17, IL-22, IL-23, IL-31, IL-33, IL-36, TNF-α, TGF-β, and IFNγ were quantified by ELISA. CBC-derived indices were computed (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Case-control comparisons used the full sample. Cytokine-index associations were evaluated in psoriasis patients using bivariate correlations and multivariate GLM adjusted for age, smoking, and NAFLD. Multiplicity was controlled using Benjamini-Hochberg false discovery rate (BH-FDR); prespecified sensitivity analyses used log-transformed cytokines and Spearman correlations.ResultsPsoriasis patients had higher levels of all cytokines (all p < 0.001) and higher SIRI versus controls (p < 0.001; q = 0.005). PIV showed a nominal case-control difference (p = 0.022) that did not remain significant after BH-FDR (q = 0.055), while NLR, PLR, and SII did not differ. In adjusted multivariate GLM, TGF-β showed a global association with the joint set of indices (Pillai's trace = 0.295; p = 0.039) that did not survive BH-FDR (q = 0.507) and was attenuated with log-transformation. Nominal univariate effects for TNF-α on SIRI (F = 4.600; p = 0.039) and PIV (F = 5.660; p = 0.023) did not remain significant after BH-FDR.ConclusionsSIRI was consistently elevated in psoriasis, whereas PIV showed a nominal difference versus controls. Across exploratory analyses, SIRI and PIV showed the most consistent directional co-variation with cytokines, but associations were modest. These findings are hypothesis-generating and support further validation in larger cohorts to determine whether CBC-derived indices can serve as scalable adjunct markers of inflammatory activity in psoriasis.Weiterlesen

Background and objectivePsoriatic arthritis (PsA) is an inflammatory, chronic and progressive musculoskeletal disease associated with psoriasis. The validation of the Spanish version of the Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) questionnaire has been published previously. The present analysis studied the performance of the PURE-4 questionnaire for the early detection of PsA one year before its diagnosis.Materials and methodsThis was an observational multicenter study, including two cross-sectional assessments, with primary data collection in routine clinical practice in Spain. Adult patients with psoriasis and confirmed not having PsA diagnosis during Assessment I completed Assessment II by the rheumatologist one year (±2 months) after answering the PURE-4 questionnaire. This work presents the results of Assessment II, to confirm/rule out the presence of PsA in patients with psoriasis one year after PURE-4 answering. The analysis, involving the results from Assessment II, will evaluate the performance of the PURE-4 questionnaire for the early detection of potential PsA in terms of sensitivity and specificity.ResultsThere were 219 evaluable patients, 56.2% male, and the mean (standard deviation [SD]) age was 46.8 (12.5) years. At one year, the PsA diagnosis was confirmed in 12 (5.5%) patients, representing 26.1% of the total number of patients with PsA diagnosed since the beginning of the study. The mean (SD) PURE-4 score was 2.4 (1.1) for patients with PsA and 1.2 (1.2) for patients without a diagnosis of PsA (p = 0.0016). The area under the receiver-operating characteristic (ROC) curve confirmed the good quality of the questionnaire (0.7618; 95% CI: 0.6530-0.8706; n = 217). PURE-4 showed a sensitivity of 75.0% and a specificity of 62.9%.ConclusionsThe PURE-4 questionnaire offers good clinimetric capabilities for the early detection of PsA with a score ≥2. Of the total number of patients with PsA, one in four were detected one year after answering positively to the questionnaire, which would help to predict which patients are at high risk of developing PsA. The authors reinforce the recommendation to closely follow up with these patients.Weiterlesen

BackgroundGiven the proinflammatory cascade elicited by tumor necrosis factor-α (TNF-α) in psoriasis, multiple TNF-α-targeted biologics have been developed for psoriasis treatment. Although systemic macromolecular biologics are widely used, a crucial therapeutic gap remains for mild-to-moderate psoriasis, underscoring an unmet need for more effective topical drugs suppressing TNF-induced inflammatory signaling.ObjectiveTo identify a novel potent natural small-molecule drug suppressing TNF-induced inflammatory signaling and elucidate its therapeutic mechanism in psoriasis.MethodsFirst, candidate small-molecule drugs were screened out through a high-throughput screening platform. Next, the therapeutic effect of Isolinderalactone was evaluated through topical application in the imiquimod (IMQ)-induced psoriasis-like mouse model. Subsequently, RNA sequencing (RNA-seq) analysis of TNF-α-stimulated HaCaT cells and epidermis of IMQ-treated mice identified key transcriptomic alterations induced by Isolinderalactone treatment. Finally, anti-psoriasis effects and underlying mechanisms of Isolinderalactone were verified in both in vivo and in vitro experiments.ResultsIsolinderalactone was identified as a potent drug suppressing TNF-related signaling with low cytotoxicity. Topical application of Isolinderalactone significantly alleviated IMQ-induced psoriasis-like dermatitis. Conjoint analysis of RNA-seq for TNF-α-stimulated HaCaT cells and epidermis from lesions of IMQ-treated mice revealed Isolinderalactone downregulated the expression of TNF-α, interleukin-17 (IL-17) and S100-related inflammatory factors in epidermal keratinocytes. Mechanistically, Isolinderalactone significantly inhibited the TNF-α/STAT3 inflammatory pathways in epidermal keratinocytes and exerted an anti-inflammatory effect.ConclusionIsolinderalactone exhibits anti-inflammatory activity through multiple mechanisms, highlighting the potential of topical Isolinderalactone therapy for mild-to-moderate psoriasis.Weiterlesen

BackgroundPsoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular compartments remain poorly understood. The aim of this study was to investigate the prevalence and determinants of bone microarchitectural damage in patients with psoriatic disease.MethodsWe performed a cross-sectional study in patients with psoriasis (PsO), psoriatic arthritis (PsA) and age-matched healthy controls (HCs) recruited into the Department of Dermatology and Rheumatology of Verona centre. We conducted high-resolution peripheral quantitative CT of the radius and finger joints of the non-dominant hand. Bone microstructure parameters and finite element analysis (uFEA) were calculated.Results51 patients with PsO and 39 patients with PsA were consecutively enrolled in the study. 24 age-matched HCs were enrolled. Distal radius total and cortical volumetric bone mineral density (Ct.BMD) levels were lower in patients with PsA and PsO compared with HC. On distal radius uFEA analysis, we found a significant reduction of stiffness in PsA compared with both HC and PsO. At the distal interphalangeal (DIP) joints, Ct.BMD and trabecular volumetric bone mineral density were lower in PsA and PsO compared with HC. Nail involvement in psoriatic disease was negatively associated with bone stiffness at the proximal and distal region of the DIPs.ConclusionPsoriatic disease negatively impacted bone integrity. Patients with psoriatic disease seemed to have lower bone density and more microarchitectural alteration that impacted on biomechanics properties. Nail involvement was associated with decreased bone stiffness in psoriatic disease.Weiterlesen

# Neue Hoffnung: Mikronadeln könnten Psoriasis besser behandeln Forscher arbeiten an einer neuen Behandlungsmethode für Psoriasis. Sie nutzen winzige Nadeln, um Wirkstoffe direkt in die Haut zu bringen.[1][3][4] Diese Mikronadeln sind so klein, dass sie kaum Schmerzen verursachen. Das ist ein großer Vorteil gegenüber normalen Injektionen. Die Idee dahinter ist clever: Die Nadeln durchstechen nur die oberste Hautschicht.[4] So gelangen Medikamente genau dorthin, wo sie wirken sollen. Gleichzeitig verursachen sie weniger Nebenwirkungen als andere Methoden. Besonders interessant ist die Behandlung mit sogenannter siRNA. Das ist ein Stoff, der bestimmte Gene in der Haut ausschalten kann.[1] Wenn man diese Gene stumm macht, können entzündliche Prozesse gehemmt werden. Das könnte die Symptome von Psoriasis verringern. Die neuen Technologien zeigen, dass Forscher ständig an besseren Lösungen arbeiten.[3][4] Die bisherigen Behandlungen helfen vielen Menschen gut. Aber neue Ansätze könnten in Zukunft noch sanfter und wirksamer sein. Patienten sollten trotzdem mit ihrem Arzt klären, welche Therapie für sie passt. Nicht jedes neue Verfahren ist sofort für alle verfügbar. Originaltitel: Transdermal siRNA delivery via biomineralized nanoparticle-incorporated microneedles modulates cuproptosis-ferroptosis interaction for psoriasis therapy Link zur Quelle

Originaltitel: Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years. Link zur Quelle

Originaltitel: Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality. Link zur Quelle

Trial number: 2023-506333-29-00 Overall trial status: Ongoing, recruiting Trial title: A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis. Medical conditions: Psoriatic arthritis, Moderate to Severe Plaque Psoriasis Status in each country: Poland:Ongoing, recruiting, Germany:Ongoing, recruiting Trial phase: Phase III and phase IV (Integrated) Therapeutic Areas: Diseases [C] - Immune System Diseases [C20] Primary end point: Composite gene expression score using reverse transcription-polymerase chain reaction (RT-PCR) in lesional skin at Baseline and Week 48 using preselected genes based on Bimekizumab mechanism of action and PSO disease biology pathways Secondary end point: 1. Treatment-emergent adverse events (TEAEs) from Baseline to the end of the Safety Follow-Up (SFU) 2. Treatment-emergent serious adverse event (TESAEs) from Baseline to the end of the SFU 3. TEAEs leading to permanent discontinuation of IMP from Baseline to the end of the SFU Age of participants: 65+ years, 18-64 years Gender of participants: Female, Male Trial region: In both EEA and non-EEA Planned number of participants: 46 Sponsor: UCB Biopharma Sponsor type: Pharmaceutical company Trial product: bimekizumab Results posted: No Overall decision date: 15/08/2024 Countries decision date: DE: 15/08/2024, PL: 26/08/2024 Last updated date: 07/03/2026View the full article

Originaltitel: Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Link zur Quelle

# HeROPA-Studie: HRO350 bei Psoriasis Die HeROPA-Studie war eine randomisierte, doppelblinde, placebokontrollierte Phase-2B-Studie, die die Wirksamkeit und Sicherheit von HRO350 bei leichter bis mittelschwerer Psoriasis untersucht hat. An der Studie nahmen über 500 Patienten in fünf europäischen Ländern teil. Das Ziel war es, festzustellen, ob HRO350 wirksam gegen Psoriasis-Symptome ist und welche Dosis am besten funktioniert. Nach dem primären Endpunkt bei 26 Wochen zeigte sich eine unerwartet hohe Placebo-Rate, doch die 52-Wochen-Daten offenbarten positive Effekte bei sekundären Endpunkten, insbesondere bei der Erreichung einer klaren oder fast klaren Haut (PGA 0/1). HRO350 wurde gut vertragen und es gab keine Sicherheitsbedenken. ## Die Substanz HRO350 HRO350 ist ein natürliches, öl-basiertes Nahrungsergänzungsmittel aus Heringsrogen. Es enthält spezielle Fettstoffe (Phospholipide) mit mehrfach ungesättigten Fettsäuren aus dem Meer – das sind eigentlich Stoffe, die auch in gesunder Ernährung vorkommen, beispielsweise in Fischöl. Studien deuten darauf hin, dass HRO350 Entzündungsprozesse im Körper bremsen kann, was bei Psoriasis hilfreich sein könnte, da diese Hautkrankheit von Entzündungen verursacht wird. HRO350 wird als weiche Kapseln zum Schlucken eingenommen – täglich mehrere Kapseln morgens und abends. --- Originaltitel: A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the 'HeROPA' study) Erkrankung: Psoriasis (leicht bis mittelschwer) Phase: Phase 2B (Therapeutic Exploratory) Firma: Arctic Bioscience AS Art der Verabreichung: Soft Capsules (oral) https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-501850-12-00

**Hauterkrankungen und Psyche: Was Psoriasis und Vitiligo verbindet** Menschen mit Hauterkrankungen kämpfen oft mit mehr als nur den sichtbaren Symptomen. Eine neue deutsche Studie zeigt jetzt, wie häufig psychische Probleme bei verschiedenen Hautkrankheiten auftreten[1]. Forscher haben Daten von fast 3 Millionen Versicherten analysiert. Sie verglichen Menschen mit Vitiligo mit Psoriasis-Patienten und anderen Gruppen[1]. Das Ergebnis ist wichtig für Sie: Menschen mit Vitiligo haben deutlich mehr Angststörungen und Depressionen als Psoriasis-Patienten. Bei Vitiligo treten diese psychischen Probleme etwa 2 bis 3 Mal häufiger auf[1]. Aber auch bei Psoriasis ist die psychische Belastung hoch. Weltweit berichten über 58 Prozent der Patienten von Depressionen oder Angst[2]. Viele vermeiden soziale Kontakte oder fühlen sich weniger selbstbewusst[2]. Die gute Nachricht: Experten fordern jetzt bessere psychologische Unterstützung für alle Patienten mit sichtbaren Hauterkrankungen. Das bedeutet, dass Ärzte künftig nicht nur die Haut, sondern auch die Psyche behandeln sollten[1][2]. Wenn Sie mit Psoriasis kämpfen und sich niedergeschlagen fühlen, sprechen Sie mit Ihrem Arzt. Psychologische Hilfe ist genauso wichtig wie Hautbehandlungen. Originaltitel: Prevalence and comparative risk of mental health disorders in persons with vitiligo: a retrospective matched cohort study using claims data with expert-informed case validation. Link zur Quelle

Trial number: 2023-506296-97-00 Overall trial status: Ongoing, recruiting Trial title: A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis Medical conditions: Moderate to Severe Plaque Psoriasis Status in each country: Germany:Ongoing, recruiting, Romania:Authorised, recruiting, Italy:Ongoing, recruiting, Belgium:Ongoing, recruiting, Poland:Ongoing, recruiting, Hungary:Ongoing, recruiting, Spain:Ongoing, recruiting Trial phase: Therapeutic confirmatory (Phase III) Therapeutic Areas: Diseases [C] - Immune System Diseases [C20] Primary end point: Efficacy: Participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16., Efficacy: Participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16., Safety (LTE): AEs and SAEs through study completion., Safety (LTE): Monitoring of growth, including body weight and height and sexual maturation, through study completion. Secondary end point: Efficacy: Participants achieving at least 90% improvement in PASI (PASI 90) Week 16., Efficacy: Change from baseline in PASI at Week 16., Efficacy: Change from baseline in BSA involvement at Week 16., Safety: Treatment emergent AEs and SAEs, laboratory parameters, physical examination, and vital signs through study completion., Safety: Participants with protective titers of antibodies to measles, tetanus, and pertussis at Week 16., Safety: Monitoring of growth including body weight and height, and sexual maturation through study completion., Efficacy (LTE): Participants achieving 75% improvement in PASI (PASI 75) over time through study completion., Efficacy (LTE): Participants achieving an sPGA score of 0 (clear) or 1(almost clear) with at least a 2-point reduction from baseline over time through study completion. Age of participants: 0-17 years Gender of participants: Female, Male Trial region: In both EEA and non-EEA Planned number of participants: 145 Sponsor: Bristol-Myers Squibb Services Unlimited Company Sponsor type: Pharmaceutical company Trial product: Placebo to match deucravacitinib 2mg minitablets in sachet, oral use, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, deucravacitinib Results posted: No Overall decision date: 08/10/2025 Countries decision date: BE: 08/10/2025, DE: 08/10/2025, HU: 10/10/2025, IT: 10/10/2025, RO: 13/10/2025, ES: 09/10/2025, PL: 10/10/2025 Last updated date: 13/10/2025View the full article

# Wenn die Haut leidet, leidet auch die Seele Menschen mit Schuppenflechte, Neurodermitis oder Hidradenitis suppurativa brauchen nicht nur eine gute Hautbehandlung. Sie benötigen auch psychologische Unterstützung. Das zeigt jetzt eine große internationale Studie mit insgesamt über eine Million Patienten.[1] Die Forschung hat ergeben: Patienten mit diesen Hauterkrankungen suchen deutlich häufiger psychologische Hilfe auf als gesunde Menschen. Bei Neurodermitis ist der Anstieg besonders groß. Diese Patienten gehen etwa dreimal häufiger zur Psychotherapie als Kontrollpersonen ohne Hauterkrankung.[1] **Aber warum ist das so?** Die chronischen Hautleiden verändern die Lebensqualität stark. Sichtbare Flecken und Ausschläge belasten viele Menschen emotional. Manche entwickeln Depressionen oder Angststörungen.[3] Zudem beeinflussen die Entzündungsprozesse in der Haut auch das Nervensystem und können Stimmung und Psyche belasten.[3] Interessant: Männer und Frauen sind unterschiedlich betroffen. Bei Neurodermitis leiden Frauen stärker unter psychischen Belastungen. Bei Schuppenflechte ist es etwas ausgewogener verteilt.[1] **Das Fazit der Studie:** Ärzte sollten Haut- und Seelenpflege gemeinsam angehen. Wer regelmäßig zur Hauttherapeut geht, sollte auch ein offenes Ohr für psychische Belastungen haben. Psychologische Hilfe gehört zur modernen Behandlung einfach dazu. Originaltitel: Psychiatric and Psychological Approach in Patients with Atopic Dermatitis, Hidradenitis Suppurativa and Psoriasis: A Propensity-Matched Real-World Cohort Study. Link zur Quelle

Originaltitel: Psychiatric and Psychological Approach in Patients with Atopic Dermatitis, Hidradenitis Suppurativa and Psoriasis: A Propensity-Matched Real-World Cohort Study - Dermatology and Therapy Link zur Quelle

Originaltitel: Editorial: Advancements in AI for the analysis and interpretation of large-scale data by omics techniques. Link zur Quelle

Originaltitel: Joint Assessment Matters: Diagnostic and Therapeutic Benefits of Interdisciplinary Psoriasis Care - Advances in Therapy Link zur Quelle

Originaltitel: Lateral hypothalamus directs stress-induced modulation of acute and psoriatic itch Link zur Quelle